SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksConvaTec Regulatory News (CTEC)

Share Price Information for ConvaTec (CTEC)

Share Price is delayed by 15 minutes
Get Live Data
202.60    2.60 (1.30%)
Bid:
203.20
Ask:
203.60
Spread: 0.40 (0.197%)
Market Cap: £3.96b
CTEC Live PriceLast checked at - London Stock Exchange

Intraday ConvaTec Share Chart

Stabilisation Notice

26 Oct 2016 07:00

RNS Number : 4526N
ConvaTec Group PLC
26 October 2016
 

Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.

ConvaTec Group plc (the "Company")

Stabilisation Notice

26 October 2016

Goldman Sachs International (contact: Craig Loftus; telephone: +44 (0)20 7774 1000) hereby gives notice that the Stabilising Manager named below and its affiliates may stabilise the offer of the following securities in accordance with the relevant provisions of the Market Abuse Regulation (EU) No 596/2014 and Commission Delegated Regulation (EU) 2016/1052.

The securities:

Issuer:

ConvaTec Group plc

Securities:

Ordinary shares ("ORDs") of the Issuer (ISIN: GB00BD3VFW73)

Offering size:

659,734,996

Offer price:

225p

Stabilisation:

Stabilising Manager:

Goldman Sachs International, Peterborough Court, 133 Fleet Street, London EC4A 2BB

Stabilisation period expected to start on:

26 October 2016 at 8:00am

Stabilisation period expected to end no later than:

25 November 2016 (close of business)

Maximum size of over-allotment facility:

15% of global offer

Trading venue where stabilisation may be undertaken:

London Stock Exchange

Over-allotment Option:

Terms:

The Over-allotment Shareholders have granted Goldman Sachs International, in its capacity as Stabilising Manager and for the account of the underwriters, the option to acquire up to an additional 98,960,249 ORDs at the Offer price.

Duration:

This option may be executed at any time during the stabilisation period.

 

Disclaimer

 

In connection with the offer of the above securities, the Stabilising Manager may over-allot the securities or effect transactions with a view to supporting the market price of the securities at a level higher than that which might otherwise prevail. However, there is no assurance that the Stabilising Manager will take any stabilisation action and any stabilisation action, if begun, may be ended at any time.

 

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.

 

This announcement and the offer of the securities to which it relates are only addressed to and directed at persons outside the United Kingdom and persons in the United Kingdom who have professional experience in matters related to investments or who are high net worth persons within article 12(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and must not be acted on or relied on by other persons in the United Kingdom.

 

In addition, if and to the extent that this announcement is communicated in, or the offer of the securities to which it relates is made in, any EEA Member State that has implemented Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the "Prospectus Directive") before the publication of a prospectus in relation to the securities which has been approved by the competent authority in that Member State in accordance with the Prospectus Directive (or which has been approved by a competent authority in another Member State and notified to the competent authority in that Member State in accordance with the Prospectus Directive), this announcement and the offer are only addressed to and directed at persons in that Member State who are qualified investors within the meaning of the Prospectus Directive (or who are other persons to whom the offer may lawfully be addressed) and must not be acted on or relied on by other persons in that Member State.

 

This announcement is not an offer of securities for sale into the United States. The securities have not been, and will not be, registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption from registration. There will be no public offer of securities in the United States. The distribution of this announcement in other jurisdictions may be restricted by law, and persons whose possession this announcement comes into should inform themselves about, and observe, such restrictions.

 

END

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STAPGGPAUUPQUUQ
Date   Source Headline
13th Sep 202212:08 pmEQSConvatec Group PLC: Scrip Dividend – Calculation Price
16th Aug 202212:00 pmEQSConvatec Group PLC: Director/PDMR Shareholding
16th Aug 202212:00 pmEQSConvatec Group PLC: Director/PDMR Shareholding
4th Aug 20227:00 amRNSInterim Results
7th Jul 202211:53 amRNSDirector Declaration
28th Jun 20225:26 pmRNSBlock listing Interim Review
31st May 20222:00 pmRNSTotal Voting Rights
19th May 202210:00 amRNSDirector/PDMR Shareholding
12th May 20224:25 pmRNSResult of AGM
12th May 20227:00 amRNSAGM Trading Update
4th May 20223:31 pmRNSScrip Dividend - Total Issued Shares
3rd May 20227:00 amRNSNotice of Forthcoming Scheduled IR Events
7th Apr 20223:45 pmRNSScrip Dividend – Calculation Price
1st Apr 20224:00 pmRNSHolding(s) in Company
31st Mar 20223:45 pmRNSTotal Voting Rights
30th Mar 202212:00 pmRNSAnnual Report and Accounts 2021 and Notice of AGM
25th Mar 20222:00 pmRNSDirector/PDMR Shareholding
23rd Mar 202211:30 amRNSDirector/PDMR Shareholding
17th Mar 20222:40 pmRNSDirector/PDMR Shareholding
17th Mar 20222:20 pmRNSBoard Change
14th Mar 20227:00 amRNSAcquisition Completion of Triad Life Sciences Inc
8th Mar 20227:00 amRNSAnnual Results
28th Feb 202211:00 amRNSNon-Executive Director Changes
10th Feb 20223:15 pmRNSHolding(s) in Company
28th Jan 20227:00 amRNSAcquisition: entry into attractive wound biologics
27th Jan 202211:00 amRNSBoard Committee Changes
20th Dec 20218:45 amRNSBlock Listing Application
16th Dec 20212:00 pmRNSNon-Executive Director appointment
9th Dec 20217:00 amRNSChief Financial Officer succession
1st Nov 20213:35 pmRNSTotal Voting Rights
29th Oct 20217:00 amRNSQ3 Trading Update
18th Oct 20214:30 pmRNSDirector/PDMR Shareholding
1st Oct 20217:00 amRNSPricing of $500M 3.875% Senior Notes due 2029
30th Sep 20211:13 pmRNSConvaTec Announces Offer of $500M Senior Notes
28th Sep 20213:15 pmRNSScrip Dividend - Total Issued Shares
9th Sep 20213:00 pmRNSScrip Dividend - Calculation Price
30th Jul 20213:45 pmRNSDirector/PDMR Shareholding
30th Jul 20217:00 amRNSInterim Results
28th Jun 202112:40 pmRNSDirector Declaration
1st Jun 202111:45 amRNSTotal Voting Rights
17th May 20213:15 pmRNSDirector/PDMR Shareholding
7th May 20212:50 pmRNSResult of AGM
29th Apr 20217:00 amRNSQ1 Trading Update
28th Apr 202112:45 pmRNSScrip Dividend - Total Issued Shares
12th Apr 20213:15 pmRNSScrip Dividend - Calculation Price
22nd Mar 20213:40 pmRNSAnnual Report and Accounts 2020 and Notice of AGM
11th Mar 20213:50 pmRNSDirector/PDMR Shareholding
5th Mar 20217:00 amRNSAnnual Results
22nd Feb 202111:30 amRNSDirector Declaration
21st Dec 202011:00 amRNSDirector Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.